543
Participants
Start Date
February 28, 2017
Primary Completion Date
December 21, 2017
Study Completion Date
November 20, 2018
Secukinumab 150 mg s.c.
150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
Secukinumab 300 mg s.c.
300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
Placebo
Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
Novartis Investigative Site, Quezon City
Novartis Investigative Site, Makati City
Novartis Investigative Site, Orosháza
Novartis Investigative Site, Kecskemét
Novartis Investigative Site, Kaposvár
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkoknoi
Novartis Investigative Site, George Town
Novartis Investigative Site, Mersin
Novartis Investigative Site, Pendik / Istanbul
Novartis Investigative Site, Izmir
Novartis Investigative Site, Manisa
Novartis Investigative Site, Batu Caves
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Xicheng Direct
Novartis Investigative Site, Shenyang
Novartis Investigative Site, Dalian
Novartis Investigative Site, Changchun
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Wuhan
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Aydin
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY